Press Release Archives - Page 20 of 24

Spectral Medical Announces that its Wholly-Owned Subsidiary Dialco Medical has been Granted FDA IDE Authorization to Conduct a Trial of DIMI for Home Hemodialysis Use

TORONTO, Canada – February 23, 2021 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), today announced that its wholly-owned subsidiary, Dialco Medical Inc. (“Dialco”), has been granted Investigational Device Exemption (IDE) authorization by the...

Spectral Medical Appoints Dr. John Kellum as Chief Medical Officer

TORONTO, CANADA – February 1, 2021 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the...

Spectral Medical to Present at the H.C. Wainwright Virtual BioConnect Conference

TORONTO, CANADA – January 11, 2021 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting...

Spectral Medical to Present at the SNN Network Canada Virtual Event on January 7, 2021

TORONTO, CANADA – January 6, 2021 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting...

Spectral Medical to Host Virtual Investor Day on December 4, 2020

TORONTO, Canada – November 27, 2020 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal...

Spectral Medical Announces that its wholly owned subsidiary Dialco Medical has received MDSAP certification

MDSAP is the highest quality and regulatory standard in the medical device industry TORONTO, Canada – November 24, 2020 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and...

« Older Entries

Next Entries »

EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc.to obtain appropriate product information for your country.